Galapagos NV’s service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca, under which BioFocus will perform medicinal chemistry, computational chemistry and support biology and ADMET services for AZ’s infection discovery program based in Boston. Total contract value for Galapagos will be $938,000. This is the third collaboration between the two companies since August 2006. BioFocus DPI is also providing chemistry and supporting biology ...